Literature DB >> 12209589

Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10.

Michael R Shurin1, Zoya R Yurkovetsky, Irina L Tourkova, Levent Balkir, Galina V Shurin.   

Abstract

As CD40 plays a key role in both antitumor immunity and DC maturation, we have studied the regulation of its expression during DC hematopoiesis (dendropoiesis) in vitro and in vivo in the tumor microenvironment. Using MC38 colon adenocarcinoma tumor models, we have demonstrated that DCs generated in vitro from bone marrow precursors obtained from tumor-bearers have significantly lower expression of CD40 molecules compared to DCs generated from tumor-free mice. Furthermore, CD40 expression on DCs isolated from the spleens of tumor-bearing mice was also significantly reduced, suggesting that tumor-derived factors inhibit CD40 expression on DCs during dendropoiesis both in vitro and in vivo. Interestingly, CD40 ligation on DCs generated from tumor-bearers did not result in inducible expression of IL-12 protein or IL-12 p40 mRNA. However, Staphylococcus aureus-induced IL-12 production by DCs was not altered in tumor-bearers, confirming that inhibition of IL-12 production by DCs generated in vitro from tumor-bearing mice was due to reduced expression of CD40 on DCs. We have also shown that MC38 tumor cells produce IL-10 and that exogenous IL-10 causes downregulation of CD40 expression on DCs. In addition, endogenous IL-10 produced by colon carcinoma cells inhibited CD40-dependent IL-12 production by DCs since tumor-induced inhibition of IL-12 production was abrogated by neutralizing anti-IL-10 antibody. Finally, systemic administration of FLT3L and/or CD40L reversed CD40 and IL-12 (p40) deficiency of DCs in tumor-bearing mice in vivo. These findings thus demonstrate that tumor-derived factors, including IL-10, inhibit CD40 expression on DCs and DC precursors and suppress their maturation and function. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12209589     DOI: 10.1002/ijc.10576

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

Review 1.  Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2010-07       Impact factor: 4.388

2.  Origin and pharmacological modulation of tumor-associated regulatory dendritic cells.

Authors:  Hua Zhong; Dmitriy W Gutkin; Baohui Han; Yang Ma; Anton A Keskinov; Michael R Shurin; Galina V Shurin
Journal:  Int J Cancer       Date:  2014-01-20       Impact factor: 7.396

3.  Natural killer cells prime the responsiveness of autologous CD4+ T cells to CTLA4-Ig and interleukin-10 mediated inhibition in an allogeneic dendritic cell-mixed lymphocyte reaction.

Authors:  Ashley Newland; Graeme Russ; Ravi Krishnan
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

4.  Enhanced immunity against hepatoma induced by dendritic cells pulsed with Hsp70-H22 peptide complexes and CD40L.

Authors:  Jian Gao; Shan Ming Luo; Ming Li Peng; Tao Deng
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-11       Impact factor: 4.553

5.  Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations.

Authors:  Ramon Kaneno; Galina V Shurin; Irina L Tourkova; Michael R Shurin
Journal:  J Transl Med       Date:  2009-07-10       Impact factor: 5.531

6.  Levels of CD40 expression on dendritic cells dictate tumour growth or regression.

Authors:  G Murugaiyan; S Martin; B Saha
Journal:  Clin Exp Immunol       Date:  2007-05-04       Impact factor: 4.330

Review 7.  Aging and the dendritic cell system: implications for cancer.

Authors:  Michael R Shurin; Galina V Shurin; Gurkamal S Chatta
Journal:  Crit Rev Oncol Hematol       Date:  2007-04-18       Impact factor: 6.312

8.  Dendritic cells in the cancer microenvironment.

Authors:  Yang Ma; Galina V Shurin; Zhu Peiyuan; Michael R Shurin
Journal:  J Cancer       Date:  2012-12-15       Impact factor: 4.207

9.  Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response.

Authors:  Joseph W Kim; Marijo Bilusic; Christopher J Heery; Ravi A Madan
Journal:  Cancers (Basel)       Date:  2012-11-22       Impact factor: 6.639

10.  T Lymphocyte Inhibition by Tumor-Infiltrating Dendritic Cells Involves Ectonucleotidase CD39 but Not Arginase-1.

Authors:  Malika Trad; Alexandrine Gautheron; Jennifer Fraszczak; Darya Alizadeh; Claire Larmonier; Collin J LaCasse; Sara Centuori; Sylvain Audia; Maxime Samson; Marion Ciudad; Francis Bonnefoy; Stéphanie Lemaire-Ewing; Emmanuel Katsanis; Sylvain Perruche; Philippe Saas; Bernard Bonnotte
Journal:  Biomed Res Int       Date:  2015-09-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.